Table 2 OS rates at 3 and 5 years (intention-to-treat population)

From: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

 

Erlotinib group (n = 37)

GC group (n = 35)

p

3-year OS rate

58.6 (42.5–74.7)

55.9 (39.2–72.6)

0.819

5-year OS rate

40.8 (24.3–57.3)

27.6 (12.1–43.1)

0.252

  1. Data are % (95% CI)
  2. CI confidence interval, GC gemcitabine plus cisplatin, OS overall survival
Back to article page